Class Action Lawsuit Filed Against Fractyl Health and Officers
Pomerantz LLP has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and certain officers for alleged violations of federal securities laws between January 13, 2025, and January 29, 2026. The suit claims that the company made misleading statements about its Revita DMR System's efficacy based on interim data from clinical trials like REMAIN-1. The lawsuit alleges that Fractyl raised tens of millions through public offerings during this period by capitalizing on positive but potentially unreliable results, which were later called into question. On January 29, 2026, the company released six-month data showing less promising outcomes than previously suggested, prompting legal action. Investors who purchased Fractyl securities within the specified class period are invited to seek appointment as lead plaintiff by October 20, 2026. The case is currently under review in the U.S. District Court for the Southern District of New York.
Tickers: $GUTS